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Poster Session I S2650.73). All patients underwent HSCT for malignancies and none who
received a reduced intensity HSCT have developed a SMN to date.
Of those with exostoses, 1 patient had received autologous HSCT
and underwent allogeneic HSCT for myelodysplastic syndrome.
The other SMNs in this group include thyroid papillary carcinoma,
osteogenic sarcoma, GIST, PNET. 3 of 4 SMNs in the control
group had received allogeneic HSCT and all 4 had thyroid papillary
carcinoma. Matched data analysis showed that exostosis cases were
less likely to have been treated with steroids for acute GVHD
(McNemar test p5 0.022) but no differences existed in other clinical
variables examined. However, cases were younger at HSCT (3.9 vs
6.3 yrs, paired t-test p 5 0.004) and had longer F/U than controls
(11.7 vs 8.8 yrs, p 5 0.003). There was no difference in time from
HSCT to SMN (or latest F/U) by Kaplan-Meier (cases5 14.9, con-
trol 5 12.7 yrs, log rank p 5 0.35). Among all 52 patients without
considering exostosis, the age at HSCT was not different for those
with SMN than without (p5 0.87). Descriptive analyses comparing
SMN occurrence in exostosis cases and controls appears in the at-
tached table. In conclusion, for occurrence of exostoses our study
showed only acute GVHD to be different between the groups, and
the likelihood of SMN was similar for cases and controls. Of the
10 SMNs, 50% were thyroid carcinomas, which are common after
low dose radiation exposure to the thyroid.Of note, 43%of the other
solid SMNs among this group occurred in the field of focal radiation
for the primary tumor, highlighting the importance of high dose fo-
cal radiation as a SMN risk.305
REDUCED TOXICITY CONDITIONING (RTC) AND ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT) IN 100 CONSECUTIVE PEDIATRIC RECIP-
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Myeloablative AlloSCT is associated with 20-40% non-relapse
mortality (NRM) in the first 100 days. NRM depends in large part
on graft source, disease and disease status and possibly intensity of
conditioning. RTC may decrease NRM but pediatric data are lim-
ited (Satwani/Cairo BBMT, 2005). We evaluated the feasibility
and toxicity of RTC-AlloSCT in 100 consecutive children (median
age 9.2366.79 yrs) with malignant disease (50) or non-malignant
disease (50) undergoing UCB (n 5 51), MFD (n 5 41), or MUD
(n 5 8) AlloSCT (89 average risk, 11 high risk). Regimens included
Busulfan (6.4-8mg/kg) + Fludarabine (150-180mg/m2) 6 ATG
(8mg/m2) (n 5 45); Cyclophosphamide (60mg/kg) + Fludarabine
(150mg/m2) 6 ATG (8mg/m2) (n 5 20); and Busulfan (12.8-
16mg/kg) + Fludarabine (150mg/m2) + Alemtuzumab (54mg/m2)
(n 5 35). Mean follow-up is 1277 61041 days. Time to neutrophil
and platelet engraftment was 19 610 days and 35 6 26.6 days, re-
spectively. Donor chimerism on day 30, 100 and 365 was 86 627,
92.6 615.8 and 93616, respectively. Cumulative incidence of
aGVHD and cGVHDwas 24.7%64.8% and 18.6%64.7%, respec-
tively. Day 100 and 5 year NRM was 4.1%62.01% and 1563.9 %,
respectively. Overall incidence of primary graft failure (PGF) was
16.5%63.7%. Incidence of PGF with UCB was 33.3%66.8% vs.
0% for MUD and MSD (p \ 0.0001). Incidence of PGF with
UCB in chemo-naive vs. non-chemo-naive patients was 48.3%6
9.3% vs. 10.5%67 % (p\ 0.0072). The 5 year probability of OS
and EFS was 69%65% and 56.4%65.4%, respectively. On univar-
iate analysis, age (p 5 0.12), malignant disease (p 5 0.1), UCB (p 5
0.02), poor risk disease (p 5 0.001), chemo-naive patients (p 5 0.1),
fungal infection (p5 0.01), alemtuzumab based RTC (p5 0.03) and
PGF (p 5 0.03) were associated with poor OS. However, on Cox
proportional hazardmodel basedmultivariate analysis only graft fail-
ure (p5 0.028) and poor risk disease (p5 0.03) were associated withpoor OS. In summary, in this largest reported pediatric series, RTC-
AlloSCTdemonstrated substantially reduced day 100NRMand sus-
tained donor chimerism. However, chemo-naive children undergo-
ing RTC-AlloSCT with UCB grafts have a higher incidence of
PGF, and poor OS.306
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Background: Steroid-refractory acute gastrointestinal graft-versus-
host disease (GvHD) remains major cause of mortality in pediatric
patients undergoing hematopoietic stem cell transplantation
(HSCT). Among newly developed agents suitable for the treatment
of GvHD, monoclonal antibodies hold much promise.
Methods: we report a series of 10 children who underwent alloge-
neic transplant from June 2007 through June 2009 and were treated
with daclizumab for steroid-refractory acute GI GvHD (grade III-
IV). Median of patients’ age was 6.27 years (range 1-11) and 8 of pa-
tients were male. 8 of 10 patients underwent myeloablative and 2 of
them nonmyeloablative stem cell transplant. Bonemarrow (BM), pe-
ripheral blood (PB), and cord blood were stem cell sources in 4 pa-
tients, 3 patients and one patient respectively. Additionally, double
cord blood in one patient and BM and PB concurrently in another
one were used. Patients were transplanted from full match related
(n5 6), one locus mismatch related (n5 1), two locus mismatch un-
related (n 5 2) and haploidentical related (n 5 1) donor because of
Thalassemia (n5 4), Acute Lymphoblastic Leukemia (n5 2), Aplas-
tic Anemia (n 5 1), Fanconi Anemia (n 5 1), Leukocyte Adhesion
Deficiency (n 5 1), and Wiskott-Aldrich Syndrome (n 5 1). After
first line therapy failed to control GvHD, Daclizumab added at
a dose of 1 mg/kg every 10-14 days until response achieved and/or
maximum 5 doses administered.
Results: 9 of 10 patients (90%) responded to Daclizumab therapy
completely, but one patient failed. There were no infusion-related
reactions. 8 patients developed CMV infection during Daclizumab
therapy. Invasive fungal and bacterial infections occurred in 6 pa-
tients following Daclizumab therapy. Seizure and Guillain-Barre
were important complications after daclizumab therapy in two pa-
tients which may be attributable to this monoclonal antibody. At
a median follow-up of 460 days, 8 patients (80%) are alive and free
of GvHD, severe infections and underlying disease. The remaining
two patients died because of bacterial meningitis and severe non-re-
sponding acute GI GvHD. Limited Chronic GvHD, occurred in 2
patients.
Conclusions:Daclizumab was able to induce complete responses in
pediatric patients with refractory acute gastrointestinal GvHD, but
is associated with morbidity and mortality due to infectious compli-
cations. Aggressive prophylaxis against viral and fungal infections is
recommended.307
A PROSPECTIVE STUDY OF REDUCED INTENSITY CONDITIONING (RIC)
IN CHILDREN UNDERGOING UNRELATED UMBILICAL CORD BLOOD
TRANSPLANTATION (UCBT) FOR NON-MALIGNANT DISEASES: PRELIMI-
NARY RESULTS DEMONSTRATE A HIGH RATE OF ENGRAFTMENT AND
LOW INCIDENCE OF GVHD
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Moffet, J., Stokhuyzen, A., Cash, J., Kurtzberg, J., Szabolcs, P. Duke
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Reduced intensity conditioning (RIC) reduces transplant related
morbidity and mortality. However, engraftment remains a challenge
after RIC in children with non-malignant disorders undergoing
UCBT.We designed a novel RIC regimen for such children to study
its efficacy to promote durable engraftment. Outcomes of 8 such
children enrolled between Dec 2008 and July 2010 are presented
in this preliminary analysis. RIC regimen consisted of alemtuzumab
(3.2mg/kg), hydroxyurea (HU), fludarabine (FLU) 150 mg/m2,
Table 1. Demographic and transplant details
No./Sex/Age (y) Diagnosis/Co-morbidities HLA match
TNC  107/kg
(cryopreserved)
Days to
ANC>500
Whole blood
chimerism/day post-tx Event Follow-up
1/M/2.03 MPS II / Cardiomyopathy 4/6 9.64 19 >98%/+623 A/W 655+
2/M/3.35 MPS IIIB 6/6 6.09 15 92%/+384 A/W 433+
3/F/3.32 MPS IIIB 5/6 6.08 28 63%/+112 Death 170
4/M/1.3 CHH 6/6 17.68 NE 0/+30 Graft failure 368+
5/M/6.76 MLD 5/6 5.88 24 >98%/+268 A/W 280+
6/F/3.32 Zap 70 def./Enteroviral meningitis, Resp.
MAI, Pseudomonas, Candida, Paraflu
5/6 8.3 21 >98%/+97 A/W 131+
7/F/0.45 HLH 5/6 22.27 19 >98%/+61 A/W 111+
8/F/0.58 HLH/Adenoviremia 4/6 14.19 20 >98%/+57 A/W 76+
Median: Age 2.67 8.97 20 280
MPS 5 mucopolysaccharidosis; CHH5Cartilage Hair Hypoplasia; MLD5Metachromatic Leukodystrophy; HLH5Hemophagocytic Lymphohistiocyto-
sis; NE5not evaluable; A/W5alive and well
S266 Poster Session Imelphalan (MEL) 140 mg/m2 and thiotepa (TT) 200mg/m2.
GVHD prophylaxis consisted of tacrolimus and MMF. All patients
received single UCBT; median age and weight at the time of trans-
plant were 3.3yrs and 15.1kg respectively; cryopreserved median cell
dose was 8.97x107 TNC/kg (range 5.9–22.3). HLA match was 4/6,
5/6 and 6/6 in 2, 4 and 2 patients respectively. Preparative regimen
was well tolerated. Maximummucositis was grade 3. To date, no pa-
tient has experienced CNS, cardiac, pulmonary or hepatorenal tox-
icity attributable to conditioning. Patient with Cartilage Hair
Hypoplasia (CHH) with no post-thaw CFU growth had autologous
recovery on day +30. He was successfully retransplanted with RIC
conditioning. The remaining patients (7 of 8) engrafted at a median
of 20 days post-transplant. At the last evaluation, whole blood donor
chimerism in engrafted patients ranged from 63% to . 98% with 6
of 7 engrafted patients. 90% donor. None of the patients have had
Grade 3-4 acute GVHD or extensive chronic GVHD thus far, al-
though follow-up for chronic GVHD is short. Untransfused platelet
count. 50K was achieved in all engrafted patients at a median of 39
days. Viral reactivation and/or de novo viral infections were seen
commonly but without appreciable end organ disease. Adenovirus
infection was noted in 5 patients (1 patient had adenoviremia that re-
solved with cidofovir and adoptive immunotherapy); the patient with
autologous recovery had prolonged CMV viremia. Seven of 8 pa-
tients are alive with a median follow-up of 280 days. One patient
with mixed chimerism died on day +170 of an acute hemolytic trans-
fusion reaction. The first two patients are off immunosuppression
with age appropriate immune profiles.
Conclusions: RIC with alemtuzumab, HU, FLU, MEL, TT is well
tolerated and results in a high rate of donor engraftment with a low
risk of GVHD and regimen related toxicity in children with chemo-
therapy na€ıve non-malignant diseases undergoing UCBT.308
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Prior to 2009, stable patients in our hematopoietic stem cell trans-
plant (HSCT) unit received routine transfusions for hemoglobin\9
g/dL. In February 2009, we changed this transfusion threshold to
Hgb\7 g/dL based on published data in critically ill but stable pe-
diatric intensive care unit patients. AIM: The aim of our study was to
assess the impact of changing to a conservative transfusion strategy in
children undergoing HSCT at our institution.
Methods:We compared census and transfusion data obtained dur-
ing primary admissions for HSCT using the prior transfusion
threshold (1/1/08-12/31/08) and after implementation of the conser-
vative transfusion threshold (3/1/09-2/28/10). All transfusion deci-
sions in both study periods were made at the discretion of
physician attendings. Data was analyzed with help from the PRU-
DENT quality improvement team, which focuses on PediatricResource Use and the Determination of Effective and Necessary
Targets at our hospital.
Results: 66 patients admitted for HSCT pre-intervention were
compared with 75 post-intervention. Pre-and post- patients were
of similar ages (median 6 (IQR 2, 12.5) vs. 6 (3, 13) yrs old, p 5
.8), and underwent similar types of transplant (22 (33%) vs. 26
(35%) autologous, p 5 .9), for similar diagnoses. Similar numbers
of patients received at least one transfusion in the two periods (65
(98.5%) vs. 72 (96%), p 5 .4). Post-intervention patients, however,
received significantly fewer RBC units (median 4 (IQR 3, 8) vs. 3
(2,5), p 5 .002) and had fewer transfusion days (median 4 (IQR
2, 5) vs. 3 (2, 5), p 5 .01). In addition, median Hgb pre-transfusion
significantly decreased from 8.8 g/dL to 6.8 g/dL (p \ .0001).
Patient outcomes appeared similar, with no differences in median
length of stay in days (37 (IQR 30, 46) vs. 37 (29, 52), p 5 .7),
median days to engraftment (20 (IQR 12, 25) vs. 18 (12, 24),
p 5 .7) or 100 Day Mortality (26% vs. 18%, p 5 .2). Finally,
median blood product related charges were significantly less
post-intervention ($3624 (IQR $2265, $6040) vs. $2185 ($1812,
$3997), p 5 .004).
Discussion: A review of our institutional experience suggests a con-
servative transfusion target of a Hgb of\7 g/dL in otherwise stable
children undergoing HSCT results in fewer transfusions without in-
creasing adverse outcomes. Further study is required to fully evaluate
the safety of this practice as well as to comprehensively assess its im-
pact on the provision of high-value, high-quality care in pediatric
HSCT units.309
CLONAL EVOLUTION IS A STRONGER PREDICTOR THAN DISEASE STATUS
OF DISEASE-FREE SURVIVAL AFTER PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Hudspeth, M.P., Chiuzan, C., Garrett-Mayer, E., Nista, E.,
Robertson, J., Wolff, D.Medical University of South Carolina, Charleston,
SC
Background: Clonal evolution as a model of tumor development
and progressionwas first proposed byNowell in 1976.Genetic insta-
bility of tumor cells leads to subpopulations with additional cytoge-
netic abnormalities. Subpopulations with cytogenetic abnormalities
that confer a survival advantage become the dominant population
leading to progression. Although clonal evolution has been generally
viewed as an adverse event, there is limited data regarding the effect
on outcome after HSCT.
Methods: We conducted a retrospective chart review of pediatric
patients who underwent HSCT for leukemia beyond CR1/CP1 or
with refractory disease from 2005-2010. Three patients with isolated
CNS relapse and two patients with JMML were excluded. Cytoge-
netic analyses from diagnosis and relapse were compared for 16 pa-
tients. Ten of these patients had clonal evolution, defined as an
additional cytogenetic abnormality from diagnosis. Relapse-free sur-
vival was analyzed using the Kaplan-Meier method and the differ-
ences between survival curves were tested using a log rank test at
a 0.05 significance level.
